These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24107972)

  • 1. Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study.
    Sjoquist KM; Friedlander ML; O'Connell RL; Voysey M; King MT; Stockler MR; Oza AM; Gillies K; Martyn JK; Butow PN
    Oncologist; 2013; 18(11):1221-8. PubMed ID: 24107972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
    Friedlander ML; Stockler M; O'Connell R; Voysey M; Oza A; Gillies K; Donovan H; Martyn J; Sjoquist K; Butow P; King MT;
    Int J Gynecol Cancer; 2014 Jun; 24(5):857-64. PubMed ID: 24844219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.
    Bonaventura A; OʼConnell RL; Mapagu C; Beale PJ; McNally OM; Mileshkin LR; Grant PT; Hadley AM; Goh JCH; Sjoquist KM; Martyn J; DeFazio A; Scurry J; Friedlander ML;
    Int J Gynecol Cancer; 2017 Jun; 27(5):900-906. PubMed ID: 28498256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.
    King MT; Stockler MR; O'Connell RL; Buizen L; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Sehouli J; Feeney A; Berton-Rigaud D; Costa DSJ; Friedlander ML;
    Qual Life Res; 2018 Jan; 27(1):59-74. PubMed ID: 29248998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feeling powerless: Locus of control as a potential target for supportive care interventions to increase quality of life and decrease anxiety in ovarian cancer patients.
    Brown AJ; Sun CC; Urbauer DL; Bodurka DC; Thaker PH; Ramondetta LM
    Gynecol Oncol; 2015 Aug; 138(2):388-93. PubMed ID: 25988961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.
    Roncolato FT; Joly F; O'Connell R; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Heitz F; Feeney A; Berton-Rigaud D; Stockler MR; King M; Friedlander M;
    Oncologist; 2017 Sep; 22(9):1117-1124. PubMed ID: 28596446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer.
    Piccirillo MC; Scambia G; Bologna A; Signoriello S; Vergote I; Baumann K; Lorusso D; Murgia V; Sorio R; Ferrandina G; Sacco C; Cormio G; Breda E; Cinieri S; Natale D; Mangili G; Pisano C; Cecere SC; Di Napoli M; Salutari V; Raspagliesi F; Arenare L; Bergamini A; Bryce J; Daniele G; Gallo C; Pignata S; Perrone F
    Ann Oncol; 2018 May; 29(5):1189-1194. PubMed ID: 29462248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mental distress, quality of life and social support in recurrent ovarian cancer patients during active chemotherapy.
    Wen Q; Shao Z; Zhang P; Zhu T; Li D; Wang S
    Eur J Obstet Gynecol Reprod Biol; 2017 Sep; 216():85-91. PubMed ID: 28738296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
    Oza A; Kaye S; Van Tornout J; Sessa C; Gore M; Naumann RW; Hirte H; Colombo N; Chen J; Gorla S; Poondru S; Singh M; Steinberg J; Yuen G; Banerjee S
    Gynecol Oncol; 2018 May; 149(2):275-282. PubMed ID: 29454514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
    Lee YC; King MT; O'Connell RL; Lanceley A; Joly F; Hilpert F; Davis A; Roncolato FT; Okamoto A; Bryce J; Donnellan P; Oza AM; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Feeney A; Kaminsky MC; Diamante K; Stockler MR; Friedlander ML;
    Int J Gynecol Cancer; 2022 Jun; 32(6):761-768. PubMed ID: 35086926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
    Roncolato F; King MT; O'Connell RL; Lee YC; Joly F; Hilpert F; Lanceley A; Yoshida Y; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Ledermann JA; Berton D; Sehouli J; Kaminsky MC; Stockler MR; Friedlander M
    Gynecol Oncol; 2024 Jun; 185():128-137. PubMed ID: 38412736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.
    van de Laar R; Zusterzeel PL; Van Gorp T; Buist MR; van Driel WJ; Gaarenstroom KN; Arts HJ; van Huisseling JC; Hermans RH; Pijnenborg JM; Schutter EM; Pelikan HM; Vollebergh JH; Engelen MJ; Inthout J; Kruitwagen RF; Massuger LF
    BMC Cancer; 2014 Jan; 14():22. PubMed ID: 24422892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
    Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
    J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.
    Rustin G; Vergote I; Micha JP; Duska LR; Reed N; Bendell J; Spitz D; Dark G; Hoch U; Tagliaferri M; Hannah AL; Garcia AA
    Gynecol Oncol; 2017 Nov; 147(2):276-282. PubMed ID: 28935273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
    Jansaka N; Suprasert P
    Asian Pac J Cancer Prev; 2014; 15(24):10837-40. PubMed ID: 25605186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer.
    King MT; Stockler MR; Butow P; O'Connell R; Voysey M; Oza AM; Gillies K; Donovan HS; Mercieca-Bebber R; Martyn J; Sjoquist K; Friedlander ML
    Int J Gynecol Cancer; 2014 Jun; 24(5):865-73. PubMed ID: 24844220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
    Luo Y; Lee M; Kim HS; Chung HH; Song YS
    Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
    Tillmanns TD; Lowe MP; Walker MS; Stepanski EJ; Schwartzberg LS
    Gynecol Oncol; 2013 Feb; 128(2):221-8. PubMed ID: 22960352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
    Oronsky B; Ray CM; Spira AI; Trepel JB; Carter CA; Cottrill HM
    Med Oncol; 2017 Jun; 34(6):103. PubMed ID: 28444622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
    Lindemann K; Gao B; Mapagu C; Fereday S; Emmanuel C; Alsop K; Traficante N; ; Harnett PR; Bowtell DDL; deFazio A
    Gynecol Oncol; 2018 Aug; 150(2):239-246. PubMed ID: 29807697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.